Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
ConclusionIn real life, ponatinib is a “niche-drug” reserved for a unique population of exceptionally young patients with CML with or without the T315I mutation. In this highly selected group, very different from the PACE cohort, ponatinib achieved high overall response rates. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of Parameters Related to the Probability of Leukemic Progression in Patients With Lower-Risk Myelodysplastic Syndrome
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Jose F. Falantes, Francisco J. Márquez-Malaver, Cristina Calderón-Cabrera, Begoña Pedrote, María L. Martino, Jose González, Ildefonso Espigado, Jose A. Pérez-SimónAbstractBackgroundThe prognosis of patients with lower-risk myelodysplastic syndrome (LR-MDS) is very heterogeneous. In addition to survival estimates, identification of factors related to the probability of leukemic progression might help prognosis assessment.Patients and MethodsThe present study is a retrospect...
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): Anuhya Kommalapati, Sri Harsha Tella, Apar Kishore Ganti, James O. ArmitageAbstractBackgroundLimited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States.Patients and MethodsWe performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the...
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
ConclusionThese findings indicate that community physicians are current in their MM management practices, with uptake of new drugs and acquaintance with results of randomized clinical trials using combinations almost concurrent with their regulatory approval and publication. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study
We present a retrospective analysis to compare the hematologic and organ response in patients who received bortezomib-based therapy before autologous stem cell transplantation (ASCT) versus those who received non–bortezomib-based therapy before ASCT and those who underwent ASCT at diagnosis.Patients and MethodsOf a total of 63 patients who underwent ASCT for light chain amyloidosis, 34 received bortezomib-based therapy before ASCT (Bor-ASCT) and 29 did not receive bortezomib therapy (non-Bor-ASCT). A greater number of patients had involvement of ≥ 3 organs and cardiac involvement in the Bor-ASCT group, sugges...
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Corrigendum
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Successful Use of Bortezomib–Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma
Publication date: July 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 7Author(s): William D. Marrero, Alexis Cruz-Chacón, Christian Castillo, Fernando CabanillasAbstractPlasmablastic lymphoma (PBL) is an unusual disorder which shares some features with myeloma. The vast majority of cases have been reported in human immunodeficiency virus (HIV) positive patients. It usually presents in the oral cavity and is considered as an aggressive lymphoma with a very poor prognosis for which there is no standard of care. Despite treatment most of the patients have a suboptimal outcome. Here we present a ca...
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Comparison of Real-time Quantitative Polymerase Chain Reaction and 8-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia
ConclusionsBased on our analysis, both FCM and PCR MRD assessment methods are sensitive in survival prediction during the induction, but we suggest FCM could not be sufficiently sensitive in later phases of treatment. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors
Publication date: Available online 4 July 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Pradnya Chopade, Luke P. AkardAbstractMost patients with chronic myeloid leukemia (CML) receiving treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs) achieve favorable responses; moreover, TKI therapy enables patients to achieve long-term survival, with survival rates similar to those of individuals without CML. This enhanced survival has resulted from the availability of multiple BCR-ABL1 TKIs with efficacy not only in frontline treatment, but importantly, also in second- and third-line treatment. Here, we review t...
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

PET based analysis can accurately predict bone marrow involvement with Mantle Cell Lymphoma
ConclusionThe ability to correctly identify bone marrow involvement utilizing FDG PET/CT based voxel analysis provides promise as a novel non-invasive method of accurate staging. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Nonsecretory and Light Chain Escape In Patients With Multiple Myeloma
ConclusionsOur study describes the largest series of NS and LC escape in MM to date. The development of this phenomenon is associated with more aggressive clinical features, frequent resistance to chemotherapy, and worse clinical outcome. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Comparison of the Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and Caucasian Patients With Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia
ConclusionThese results suggest that mutational analysis is invaluable for choosing an appropriate second-line TKI in Asia. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 10, 2018 Category: Cancer & Oncology Source Type: research

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes
Publication date: Available online 23 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Valeria SantiniAbstractIn the past few months, 2 main streams of research have dominated the panorama of myelodysplastic syndrome (MDS) investigations: deepening the insight into the pathogenic role, hierarchy, and prognostic effect of somatic mutations and, as a consequence, into the effect of inherited congenital predisposing conditions and the second, quite interlinked with the first, analyzing inflammation and innate immunity in patients with MDS. The research devoted to clarifying the mechanisms of action and mechani...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience
ConclusionAutologous HCT is an effective therapy for refractory/relapsed HAL with manageable toxicity, similar to non-HIV patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms
Publication date: Available online 23 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Anita Geevarghese, John MascarenhasAbstractChronic myelomonocytic leukemia (CMML) is a relatively uncommon hematologic malignancy that manifests as peripheral monocytosis, has varying degrees of bone marrow dysplasia, and is associated with poor outcomes. Despite a growing appreciation of the pathobiologic mechanisms driving CMML, current therapies have not clearly demonstrated any survival benefit. The complex pathobiology of CMML highlights the intricate aberrantly activated cellular pathways that influence disease phen...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma
Publication date: Available online 23 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Pilar Nava-ParadaAbstractCombination regimens with anti-CD20 agents might improve the outcomes of patients with relapsed or refractory B-cell malignancies; however, the available comparative clinical evidence is limited. The present review assessed the reported evidence on the efficacy of anti-CD20 monoclonal antibodies combined with chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), or diffuse large B-cell l...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat
Publication date: Available online 24 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jamie D. Cavenagh, Rakesh PopatAbstractRecent advances in treatment have extended the survival of patients with multiple myeloma. This improvement in itself poses challenges because of the length of time that patients live with myeloma, its physical complications, and toxicities of treatment. Thus, improvements in maintaining quality of life are essential, and part of this challenge involves learning how to optimally use new therapeutic agents. Panobinostat is the first histone deacetylase inhibitor approved for the treat...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Acute Liver Failure Associated With Pomalidomide Therapy for Multiple Myeloma
Publication date: Available online 26 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lauren Reed-Guy, Maarouf A. Hoteit, Alfred L. Garfall (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis
Publication date: Available online 26 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yazan Migdady, John Barnard, Najla Al Ali, David P. Steensma, Amy DeZern, Gail Roboz, Guillermo Garcia-Manero, Mikkael A. Sekeres, Rami S. KomrokjiAbstractBackgroundRecurrent somatic mutations in SF3B1 have been identified in patients with myelodysplastic syndromes (MDS) and are associated with ring sideroblasts (RS) and relatively favorable clinical outcomes. The 2016 World Health Organization classification categorizes patients with ≥ 5% RS and SF3B1 mutation as MDS-RS, in contrast to its prior MDS-RS classifica...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Impact of FLT3 Receptor (CD135) Detection by Flow Cytometry on Clinical Outcome of Adult Acute Myeloid Leukemia Patients
Publication date: Available online 26 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Eman Z. Kandeel, Ghada El Sayed, Nahla Elsharkawy, Dalia Negm Eldin, Hanan R. Nassar, Dalia Ibrahiem, Randa Amin, Marwa Hanafi, Mohamed Khalil, Azza KamelAbstractBackgroundThe significance of FMS-like tyrosine kinase 3 (FLT3)-ITD mutation in acute myeloid leukemia (AML) prognosis has been well established. The aims of this study were to investigate the prognostic impact of the FLT3 protein (CD135) expression and its association with FLT3-ITD mutation, and to identify its role in minimal residual disease.Patients and Metho...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Aseptic Meningitis as a Complication of Daratumumab Therapy
Publication date: Available online 28 May 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kimaya Reddy, Myo Htut, Amrita Krishnan, Sanjeet S. Dadwal (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response
ConclusionEven in CR patients, outcomes were improved by an intensified approach with HDT-ASCT consolidation and lenalidomide-based maintenance therapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
ConclusionThese data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hypomethylating Agents-associated Infections—Systematic Review and Meta-analysis of Randomized Controlled Trials
ConclusionTreatment with HMAs was associated with an increase in the grade 3/4 infection rate. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma
ConclusionAlthough the overall risk of SCs in patients with HL declined after modifications in HL treatment, the risk did not change significantly at most individual sites. Thus, close follow-up with active surveillance for SCs is crucial for long-term survivors of HL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia
ConclusionWe conclude that WM cells produce CCL-3 and possibly enhance the production of RANKL in the bone microenvironment. The correlation of sRANKL and CCL-3 with survival reveals the importance of these cytokines in disease biology and highlights the significance of the interactions between WM and stromal cells for the development of WM. Finally, these findings provide the rationale for the use of anti-RANKL and anti–CCL-3 drugs in animal models of WM before their clinical evaluation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Editorial Board
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Table of Contents
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Nigel Deekes, Valentín Garcia-Gutiérrez, Jan de Jong, Šarūnas Narbutas, Peter Westerweel, Daniela ZackovaAbstractTreatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is now available, patients’ questions...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Steven M. Bair, Anthony Mato, Jakub SvobodaAbstractClassical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpo...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis
The objective of the study was to evaluate through meta-analysis the pooled proportions of patients responding to each therapeutic agent. We conducted a systematic review and meta-analysis to estimate the pooled response rate to modern hairy cell leukemia therapies. Articles published between January 1992 and August 2017 were identified by searching PubMed, Web of Science, and the Cochrane Library. Weighted meta-analysis of proportion using a random-effects model was performed for each treatment option. Of 3287 articles viewed, 20 articles describing 21 studies were included in the meta-analysis. The pooled random effect o...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
ConclusionOverall, data from the PANEX trial support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest the potential tolerability benefits of subcutaneous bortezomib in this regimen. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Serum Free Light Chain Difference and β2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis
ConclusionThe incidence of thromboembolism was substantial in those with AL amyloidosis. A greater FLC difference and for β2MG levels were risk factors for thromboembolic events. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
ConclusionSC Btz is associated with better tolerance; however, IV administration achieves a faster and deeper response in Chinese patients with newly-diagnosed multiple myeloma. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma
Conclusion18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Extralymphatic Disease Is an Independent Prognostic Factor in Hodgkin Lymphoma
ConclusionExtralymphatic disease in patients with Hodgkin lymphoma is a rare occurrence (16%) associated with poor clinical outcome. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Treating Adult Acute Lymphoblastic Leukemia in Brazil—Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen
ConclusionIntensified chemotherapy protocols for adult ALL have succeeded in achieving better survival rates in adults, especially younger adults. The low overall survival found with GMALL in Brazil's public hospital denotes the importance of optimizing the adaptations of international protocols for treatment of ALL in nondeveloped countries and, in parallel, improving supportive care in public services. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Raja Pramanik, Anudishi Tyagi, Anita Chopra, Akash Kumar, Sreenivas Vishnubhatla, Sameer BakhshiAbstractBackgroundThe purpose of our study was to evaluate the clinical, cytogenetic, and molecular features, and survival outcomes in patients with acute myeloid leukemia (AML) with myeloid sarcoma (MS) and compare them with patients with AML without MS.Patients and MethodsThis was a retrospective analysis of de novo pediatric AML patients with or without MS diagnosed at our cancer center between June 2003 and June 2016....
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study
ConclusionElevated ferritin at diagnosis may indicate tumor burden in patients with AML and predict worse EFS in the high-risk group. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature
ConclusionThe frequency of most chromosomal rearrangements successfully identified in our study and their lineage correlated with those reported in the published data. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
ConclusionThe present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
ConclusionEntospletinib monotherapy at 800 mg twice daily demonstrated limited activity in patients with advanced, relapsed DLBCL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
ConclusionThe combination of bortezomib and vorinostat is safe and has modest activity in MCL and limited activity in DLBCL. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Bone Health and Survival in Women with Multiple Myeloma
ConclusionHigher fracture risk, measured by FRAX, was associated with higher MM mortality in post-menopausal women, independent of many other clinical factors. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis
In conclusion, mutations in IDH, SRSF2, and ASXL1 had worse prognosis in OS with HRs around 2. JAK2 and SRSF2 mutation were not associated with increased leukemia transformation. The adverse effect of triple-negative, which was often compared with CALR mutation, needs to be explored. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study
This study aimed to evaluate correlates of TKI NA using EM and test the diagnostic accuracy of subjective adherence measures.Patients and MethodsCML patients receiving a TKI for any duration were enrolled at 4 hematology institutes, and adherence was measured for 4 months. EM adherence was the reference adherence measure, expressed as the percentage of days with the drug taken as prescribed. Subjective adherence was measured using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) self-report and clinician-reported visual analog scale (VAS) at 2 time points. Baseline theory–derived corr...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Prevalence of Monoclonal Gammopathy of Undetermined Significance in India—A Hospital-based Study
ConclusionTo the best of our knowledge, the present study is the first systematic study on the prevalence of MGUS in an Indian population. The overall prevalence of MGUS was 1.43% in the evaluated Indian cohort, lower than that reported for white and black populations. The incidental detection of 6 subjects with multiple myeloma of 3429 screened subjects in our study was high compared with the reported incidence of multiple myeloma in India of only 1.9 per 100,000 persons. This finding indicates the need to create awareness about myeloma-related symptoms and screening studies in appropriate age groups, at least in the hosp...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

FLT3-TKD mutations associated to NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia
Publication date: Available online 13 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marielle Perry, Sarah Bertoli, Clément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne PaubelleAbstractOutcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial. Herein we present a retrospective study of 126 newly diagnosed AML patients performed in two French centers. FLT3-TKD mutations represented 12.7% of patients, whil...
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Hodgkin Lymphoma With Multiple Autoimmune Disorders: Case Report and Review of the Literature
Publication date: Available online 15 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Natalie S. Grover, Christopher E. Dittus, Alice D. Ma, Steven I. Park (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research

Interim PET-CT result is not predictive of survival in patients with MYC-rearranged non-Burkitt aggressive B cell lymphoma
ConclusionAlthough patients with MYC-R lymphoma are reported to be at high risk for primary treatment failure, this is not predicted by iPET +, and it is not recommended that the result of iPET be used to guide changes in management of front-line or consolidative therapy for these patients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2018 Category: Cancer & Oncology Source Type: research